Stanislav Glezer
Director/Board Member at Diabetes Foundation of New Jersey
Net worth: 207 678 $ as of 2024-04-29
Profile
Dr. Stanislav Glezer is a Chief Medical Officer & Executive Vice President at Inogen, Inc. and a Worldwide Vice President-Medical Affairs at Becton, Dickinson & Co. He is on the Board of Directors at Diabetes Foundation of New Jersey. Dr. Glezer was previously employed as a Chief Medical Officer by Adocia SA and a Vice President-Global Medical Affairs by Novo Nordisk, Inc. He received his MBA from California Coast University and a doctorate degree from Yevdokimov MSUMD.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INOGEN, INC.
0.14% | 2024-04-30 | 32,049 ( 0.14% ) | 207 678 $ | 2024-04-29 |
Stanislav Glezer active positions
| Companies | Position | Start |
|---|---|---|
| Diabetes Foundation of New Jersey | Director/Board Member | 2019-07-23 |
Former positions of Stanislav Glezer
| Companies | Position | End |
|---|---|---|
| INOGEN, INC. | Chief Tech/Sci/R&D Officer | 2024-05-02 |
| BECTON, DICKINSON AND COMPANY | Chief Tech/Sci/R&D Officer | 2021-05-31 |
| ADOCIA | Chief Tech/Sci/R&D Officer | 2018-04-30 |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Chief Tech/Sci/R&D Officer | 2017-02-28 |
| Sanofi SA | Corporate Officer/Principal | - |
Training of Stanislav Glezer
| California Coast University | Masters Business Admin |
| Yevdokimov MSUMD | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| BECTON, DICKINSON AND COMPANY | Health Technology |
| INOGEN, INC. | Health Technology |
| ADOCIA | Health Technology |
| Private companies | 3 |
|---|---|
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
| Sanofi SA | Health Technology |
| Diabetes Foundation of New Jersey |
- Stock Market
- Insiders
- Stanislav Glezer
